We use cookies to improve your experience. By your continued use of this site you accept such use.
EVA Pharma

  • Multimedia content

  • Images (1)
    • Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt
  • All (1)
Source: EVA Pharma |

Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt

This milestone stems from the companies’ collaboration to expand access to affordable insulin to one million people living with diabetes in low-to middle-income countries annually by 2030

The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma (www.EVAPharma.com) through a collaboration with Eli Lilly and Company (NYSE: LLY). Launched in 2022, the collaboration aims to deliver a sustainable supply of high-quality, affordable human and analog insulin to at least one million people annually living with…

EVA Pharma

  • Multimedia content

  • Images (3)
    • EVA Pharma Signs a Voluntary Licensing Agreement with Gilead to Increase Access to Lenacapavir in 120 Countries with High Human Immunodeficiency Virus (HIV) Incidence and Limited Resources
    • EVA Pharma Signs a Voluntary Licensing Agreement with Gilead to Increase Access to Lenacapavir in 120 Countries with High Human Immunodeficiency Virus (HIV) Incidence and Limited Resources (FR)
    • EVA Pharma Signs a Voluntary Licensing Agreement with Gilead to Increase Access to Lenacapavir in 120 Countries with High Human Immunodeficiency Virus (HIV) Incidence and Limited Resources (AR)
  • All (3)
Source: EVA Pharma |

EVA Pharma Signs a Voluntary Licensing Agreement with Gilead to Increase Access to Lenacapavir in 120 Countries with High Human Immunodeficiency Virus (HIV) Incidence and Limited Resources

Under this royalty-free voluntary licensing agreement EVA Pharma will manufacture and supply Lenacapavir active pharmaceutical ingredient and finished pharmaceutical product

EVA Pharma (www.EVAPharma.com) announced today a non-exclusive, royalty-free voluntary licensing agreement signed with Gilead (https://apo-opa.co/4dB3Nwx), allowing EVA Pharma to manufacture and supply generic lenacapavir in form of active pharmaceutical ingredient and finished pharmaceutical product. This agreement includes the technology transfer of know-how to make and use lenacapavir allowing for sustainable accessibility…

EVA Pharma

  • Multimedia content

  • Images (3)
    • Biologics Facility Tour
    • EVA Pharma Completes New Biologics Facility as Part of Insulin Collaboration with Lilly
    • EVA Biologics Group Photo
  • All (3)
Source: EVA Pharma |

EVA Pharma Completes New Biologics Facility as Part of Insulin Collaboration with Lilly

The new facility has production capacity of 90 million vials and 50 million cartridges of high-quality insulin to meet the needs of at least one million people annually in Africa, as part of collaboration with Lilly

EVA Pharma (https://www.EVAPharma.com) is celebrating the completion of its new biologics’ facility in Cairo, which is set to start producing high-quality insulin next month as part of an ongoing collaboration with Eli Lilly and Company to expand sustainable access to the essential medical product. In a first for both companies,…

EVA Pharma

  • Multimedia content

  • Images (5)
    • Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa (1)
    • Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa (2)
    • Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa (3)
    • Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa (4)
    • Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa (5)
  • All (5)
Source: EVA Pharma |

Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa

For the first time, Lilly will supply API at a significantly reduced price along with pro-bono technical assistance, enabling EVA Pharma to manufacture and supply insulin to at least one million people in lower income countries

Eli Lilly and Company (NYSE: LLY) and EVA Pharma (http://www.EVAPharma.com/) announced today a collaboration to deliver a sustainable supply of high-quality, affordable human and analogue insulin to at least one million people living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs), most of which are…

EVA Pharma

  • Multimedia content

  • Videos (1)
    • Remdesivir from our hands to yours - Manufacturing Process
  • Images (5)
    • Supporting India amid COVID-19 surge (1)
    • Supporting India amid COVID-19 surge (2)
    • Supporting India amid COVID-19 surge (3)
    • Supporting India amid COVID-19 surge (4)
    • Supporting India amid COVID-19 surge (5)
  • All (6)
Source: EVA Pharma |

Supporting India amid COVID-19 surge

EVA Pharma signed a contract with the Indian government to export 300,000 vials of Remdesivir

EVA Pharma’s (www.EVAPharma.com) timely shipments of Remdesivir reached India during a major wave of coronavirus cases. When India experienced an unexpected COVID-19 surge this spring, the rapid increase in cases put pressure on the local pharmaceutical industry to supply the medicines needed. In April, EVA Pharma signed a contract with…